Ptc Therapeutics Current Ratio Growth & History (PTCT)
Ptc Therapeutics's current ratio was 2.35 for fiscal 2025.
View full Ptc Therapeutics company overviewPtc Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.35 | −0.00 | −0.10% |
| 2024 | 2024-12-31 | 2.35 | 0.33 | +16.32% |
| 2023 | 2023-12-31 | 2.02 | 0.31 | +18.31% |
| 2022 | 2022-12-31 | 1.71 | −0.17 | −8.85% |
| 2021 | 2021-12-31 | 1.87 | −2.57 | −57.81% |
| 2020 | 2020-12-31 | 4.44 | 1.14 | +34.42% |
| 2019 | 2019-12-31 | 3.30 | 1.38 | +71.76% |
| 2018 | 2018-12-31 | 1.92 | −1.11 | −36.63% |
| 2017 | 2017-12-31 | 3.04 | −2.23 | −42.35% |
| 2016 | 2016-12-31 | 5.27 | −2.58 | −32.86% |
| 2015 | 2015-12-31 | 7.84 | −2.12 | −21.29% |
| 2014 | 2014-12-31 | 9.96 | −1.08 | −9.76% |
| 2013 | 2013-12-31 | 11.04 | 10.88 | +6666.25% |
| 2012 | 2012-12-31 | 0.16 | — | — |
Ptc Therapeutics quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.39 | −0.23 | −6.24% |
| Q1 2026 | 2026-03-31 | 2.44 | −1.45 | −37.27% |
| Q4 2025 | 2025-12-31 | 2.35 | −0.00 | −0.10% |
| Q3 2025 | 2025-09-30 | 2.32 | 0.22 | +10.45% |
| Q2 2025 | 2025-06-30 | 3.62 | 1.39 | +62.58% |
| Q1 2025 | 2025-03-31 | 3.89 | 1.86 | +91.26% |
| Q4 2024 | 2024-12-31 | 2.35 | 0.33 | +16.32% |
| Q3 2024 | 2024-09-30 | 2.10 | 1.00 | +91.11% |
| Q2 2024 | 2024-06-30 | 2.23 | 0.99 | +79.88% |
| Q1 2024 | 2024-03-31 | 2.03 | 0.65 | +46.46% |
| Q4 2023 | 2023-12-31 | 2.02 | 0.31 | +18.31% |
| Q3 2023 | 2023-09-30 | 1.10 | −0.13 | −10.83% |
| Q2 2023 | 2023-06-30 | 1.24 | 0.01 | +1.11% |
| Q1 2023 | 2023-03-31 | 1.39 | −0.23 | −14.45% |
| Q4 2022 | 2022-12-31 | 1.71 | −0.17 | −8.85% |
| Q3 2022 | 2022-09-30 | 1.23 | −0.94 | −43.34% |
| Q2 2022 | 2022-06-30 | 1.22 | −2.44 | −66.59% |
| Q1 2022 | 2022-03-31 | 1.62 | −2.85 | −63.70% |
| Q4 2021 | 2021-12-31 | 1.87 | −2.57 | −57.81% |
| Q3 2021 | 2021-09-30 | 2.17 | −2.73 | −55.66% |
| Q2 2021 | 2021-06-30 | 3.66 | 0.67 | +22.25% |
| Q1 2021 | 2021-03-31 | 4.47 | 1.29 | +40.70% |
| Q4 2020 | 2020-12-31 | 4.44 | 1.14 | +34.42% |
| Q3 2020 | 2020-09-30 | 4.90 | 0.50 | +11.48% |
| Q2 2020 | 2020-06-30 | 3.00 | 0.27 | +9.79% |
| Q1 2020 | 2020-03-31 | 3.18 | −0.17 | −5.09% |
| Q4 2019 | 2019-12-31 | 3.30 | 1.38 | +71.76% |
| Q3 2019 | 2019-09-30 | 4.40 | 1.67 | +61.30% |
| Q2 2019 | 2019-06-30 | 2.73 | −1.61 | −37.15% |
| Q1 2019 | 2019-03-31 | 3.35 | 0.02 | +0.64% |
| Q4 2018 | 2018-12-31 | 1.92 | −1.11 | −36.63% |
| Q3 2018 | 2018-09-30 | 2.73 | −0.35 | −11.42% |
| Q2 2018 | 2018-06-30 | 4.34 | 1.01 | +30.12% |
| Q1 2018 | 2018-03-31 | 3.33 | −1.97 | −37.21% |
| Q4 2017 | 2017-12-31 | 3.04 | −2.23 | −42.35% |
| Q3 2017 | 2017-09-30 | 3.08 | −2.66 | −46.34% |
| Q2 2017 | 2017-06-30 | 3.34 | −3.59 | −51.84% |
| Q1 2017 | 2017-03-31 | 5.30 | −2.14 | −28.74% |
| Q4 2016 | 2016-12-31 | 5.27 | −2.58 | −32.86% |
| Q3 2016 | 2016-09-30 | 5.74 | −6.39 | −52.68% |
| Q2 2016 | 2016-06-30 | 6.93 | −4.53 | −39.53% |
| Q1 2016 | 2016-03-31 | 7.44 | −4.68 | −38.64% |
| Q4 2015 | 2015-12-31 | 7.84 | −2.12 | −21.29% |
| Q3 2015 | 2015-09-30 | 12.12 | −0.25 | −2.01% |
| Q2 2015 | 2015-06-30 | 11.46 | −8.42 | −42.35% |
| Q1 2015 | 2015-03-31 | 12.12 | −14.87 | −55.09% |
| Q4 2014 | 2014-12-31 | 9.96 | −1.08 | −9.76% |
| Q3 2014 | 2014-09-30 | 12.37 | 0.87 | +7.53% |
| Q2 2014 | 2014-06-30 | 19.88 | 11.39 | +133.99% |
| Q1 2014 | 2014-03-31 | 26.99 | — | — |
| Q4 2013 | 2013-12-31 | 11.04 | 10.88 | +6666.25% |
| Q3 2013 | 2013-09-30 | 11.50 | — | — |
| Q2 2013 | 2013-06-30 | 8.50 | — | — |
| Q4 2012 | 2012-12-31 | 0.16 | — | — |
Ptc Therapeutics current ratio trends
Over the last five fiscal years, Ptc Therapeutics's current ratio decreased from 4.44 to 2.35, a change of −2.09. The latest reported quarter, Q2 2026, shows 3.39.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ptc Therapeutics source filings ↗Community posts
PTC raises its revenue forecast as Sephience sales expand
PTC Therapeutics ($PTCT) raised its full-year 2026 revenue expectation to $1.29–$1.32 billion and increased product-sales guidance to $960–$990 million from $850–$950 million. Third-quarter 2026 product and royalty revenue reached $357.6 mi ...